Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: -adrenoreceptor antagonist, has been effective in alleviating nightmares associated with post-traumatic stress disorder (PTSD) in military veterans. METHODS: We recruited veterans from 13 Department of Veterans Affairs medical centers who had chronic PTSD and reported frequent nightmares. Participants were randomly assigned to receive prazosin or placebo for 26 weeks; the drug or placebo was administered in escalating divided doses over the course of 5 weeks to a daily maximum of 20 mg in men and 12 mg in women. After week 10, participants continued to receive prazosin or placebo in a double-blind fashion for an additional 16 weeks. The three primary outcome measures were the change in score from baseline to 10 weeks on the Clinician-Administered PTSD Scale (CAPS) item B2 ("recurrent distressing dreams"; scores range from 0 to 8, with higher scores indicating more frequent and more distressing dreams); the change in score from baseline to 10 weeks on the Pittsburgh Sleep Quality Index (PSQI; scores range from 0 to 21, with higher scores indicating worse sleep quality); and the Clinical Global Impression of Change (CGIC) score at 10 weeks (scores range from 1 to 7, with lower scores indicating greater improvement and a score of 4 indicating no change). RESULTS: A total of 304 participants underwent randomization; 152 were assigned to prazosin, and 152 to placebo. At 10 weeks, there were no significant differences between the prazosin group and the placebo group in the mean change from baseline in the CAPS item B2 score (between-group difference, 0.2; 95% confidence interval [CI], -0.3 to 0.8; P=0.38), in the mean change in PSQI score (between-group difference, 0.1; 95% CI, -0.9 to 1.1; P=0.80), or in the CGIC score (between-group difference, 0; 95% CI, -0.3 to 0.3; P=0.96). There were no significant differences in these measures at 26 weeks (a secondary outcome) or in other secondary outcomes. At 10 weeks, the mean difference between the prazosin group and the placebo group in the change from baseline in supine systolic blood pressure was a decrease of 6.7 mm Hg. The adverse event of new or worsening suicidal ideation occurred in 8% of the participants assigned to prazosin versus 15% of those assigned to placebo. CONCLUSIONS: In this trial involving military veterans who had chronic PTSD, prazosin did not alleviate distressing dreams or improve sleep quality. (Funded by the Department of Veterans Affairs Cooperative Studies Program; PACT ClinicalTrials.gov number, NCT00532493 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a position paper by the American Academy of Sleep Medicine (AASM) has highlighted a contradictory study [33] and downgraded its recommendation for prazosin, but still considers it to be the first-line pharmacological choice [34].”
From Nightmare Disorder and Isolated Sleep Paralysis (2021) · cites this paper as [33]
Citations
Cites
1 retracted
Pietrzak, R. H., Gallezot, J.-D., Ding, Y.-S., Henry, S., Potenza, M. N., Southwick, S. M., Krystal, J. H., Carson, R. E., & Neumeister, A. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.399 · Cited by 127
RetractedThe PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Bush, K. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.16.1789 · Cited by 6,196
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Substance Use Disorders in Patients With Posttraumatic Stress Disorder: A Review of the Literature
Jacobsen, L. K., Southwick, S. M., & Kosten, T. R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1184 · Cited by 1,041
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Self-citationRaskind, M. A., Peskind, E. R., Kanter, E. D., Petrie, E. C., Radant, A., Thompson, C. E., Dobie, D. J., Hoff, D., Rein, R. J., Straits-Tröster, K., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.371 · Cited by 607
Self-citation
Research works printed but not linked: 3
- Guy W. CDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976.
- Frisch MB. Manual and treatment guide for the Quality of Life Inventory (QOLI). Minneapolis: Pearson Assessments 1994.
- The Management of Posttraumatic Stress Disorder Working Group. VA/DoD clinical practice guideline for the management of posttraumatic stress disorder. Washington, DC: Department of Veterans Affairs, Department of Defense, 2010.
Cited by
Items 101–200 of 355
Jou, Y. C., & Pace-Schott, E. F. (2022) · Sleep Health · doi:10.1016/j.sleh.2022.09.003 · Cited by 21
Trauma-Associated Sleep Disturbances: a Distinct Sleep Disorder?
Rachakonda, T. D., Balba, N. M., & Lim, M. M. (2018) · Current Sleep Medicine Reports · doi:10.1007/s40675-018-0119-2 · Cited by 22
Dowd, S. M., Zalta, A. K., Burgess, H. J., Adkins, E. E., Valdespino-Hayden, Z., & Pollack, M. H. (2020) · World Journal of Psychiatry · doi:10.5498/wjp.v10.i3.21 · Cited by 19
Neuromelanin-sensitive MRI for mechanistic research and biomarker development in psychiatry
Wengler, K., Trujillo, P., Cassidy, C., & Horga, G. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01934-y · Cited by 22
Repantis, D., Wermuth, K., Tsamitros, N., Danker‐Hopfe, H., Bublitz, C., Kühn, S., & Dresler, M. (2020) · European Journal of Psychotraumatology · doi:10.1080/20008198.2020.1740492 · Cited by 19
“A1-adrenergic receptor antagonists such as the REM-enhancing prazosin (Taylor et al., 2008) have been used with some success in the treatment of PTSD-related nightmares (although newer research has questioned this practice s. Raskind et al., 2018).”
MethodHuang, Y., Xu, C., Zeng, T., Li, Z., Xia, Y., Tao, G., Zhu, T., Lu, L., Li, J., Huang, T., et al. (2021) · The Korean journal of pain · doi:10.3344/kjp.2021.34.2.210 · Cited by 18
“The PSQI scores range from 0 to 21, with higher scores indicating worse sleep quality [15].”
BackgroundPost-Traumatic Stress Disorder
Chavez, B., & Kavanagh, K. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.ptsd_overview · Cited by 18
Back, S. E., Flanagan, J. C., Jones, J. L., Augur, I. F., Peterson, A. L., Young‐McCaughan, S., Shirley, D. W., Henschel, A. V., Joseph, J. E., Litz, B. T., et al. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.08.009 · Cited by 22
Ketamine for PTSD: Well, Isn’t That Special
Stein, M. B., & Simon, N. M. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20121677 · Cited by 19
Self-citationHendrickson, R. C., Thomas, R. G., Schork, N. J., & Raskind, M. A. (2020) · Frontiers in Digital Health · doi:10.3389/fdgth.2020.00013 · Cited by 17
“The risk of under enrolling acutely symptomatic patients in a PG-RCT may be particularly high in contexts where the treatment in question or treatments very similar to it are already in active clinical use (4), as is often the case in clinical trials designed to address questions in the realm of personalized medicine.”
BackgroundMethodSelf-citationHuang, C.-Y., Zhao, Y.-F., Zhang, Z., Liu, R.-B., Liu, J.-L., Li, X., Luo, J., Li, Y., & Zhang, C. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2381696 · Cited by 19
Low-dose clonidine in veterans with Posttraumatic stress disorder
Burek, G. A., Waite, M. R., Heslin, K., Liewen, A. K., Yaqub, T. M., & Larsen, S. E. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.03.008 · Cited by 18
Meng, X., Xu, X., Wang, Z., Liang, Y., & Zhao, Y. (2022) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c02890 · Cited by 17
Impact of Traumatic Stress on Sleep and Management Options in Women
Kobayashi, I., & Howell, M. K. (2018) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2018.04.009 · Cited by 17
Waltman, S. H., Landry, J. M., Pujol, L. A. M., & Moore, B. A. (2019) · Professional Psychology Research and Practice · doi:10.1037/pro0000275 · Cited by 18
“, 2010; Nappi, Drummond, & Hall, 2012), although recent concerns have been raised regarding its efficacy (Raskind et al., 2018).”
BackgroundPrazosin for Post-Traumatic Stress Disorder.
Raskind, M. A., & Peskind, E. R. (2018) · PubMed · doi:10.1056/nejmc1803171 · Cited by 6
“A June 2018 literature search identified two randomized controlled trials (RCTs) published after the earlier literature search was conducted for the 2017 VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder.”
ResultInfluentialSelf-citationClinical and polysomnographic features of trauma associated sleep disorder
Brock, M. S., Matsangas, P., Creamer, J. L., Powell, T. A., Hansen, S. L., Foster, S. N., Self, T. C., & Mysliwiec, V. (2022) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10214 · Cited by 20
Duek, O. A., Pietrzak, R. H., Petrakis, I. L., Hoff, R. A., & Harpaz‐Rotem, I. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.10.005 · Cited by 17
Scribble co-operatively binds multiple α1D-adrenergic receptor C-terminal PDZ ligands
Janezic, E. M., Harris, D.-A., Dinh, D., Lee, K.-S., Stewart, A., Hinds, T. R., Hsu, P. L., Zheng, N., & Hague, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-50671-6 · Cited by 15
Post-traumatic stress disorder in burn patients – A large database analysis
Iglesias, N. J., Campbell, M. S., Dabaghi, E., Prasai, A., Ben-Aissa, A., Ozhathil, D. K., Jay, J. W., Song, J., Golovko, G., Wolf, S. E., et al. (2024) · Burns · doi:10.1016/j.burns.2023.12.016 · Cited by 15
Drug treatment strategies for insomnia in patients with post-traumatic stress disorder
Akinnusi, M. E., & Solh, A. A. E. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1574745 · Cited by 16
“conclusions [106] further highlighting the need to base future”
BackgroundA Review of MDMA-Assisted Therapy for Posttraumatic Stress Disorder
Lewis, B. R., & Byrne, K. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20220088 · Cited by 16
Mendes, T. P., Pereira, B. G., Coutinho, E. S. F., Melani, M., Neylan, T. C., & Berger, W. L. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111253 · Cited by 17
Gonda, X., Döme, P., Erdelyi-Hamza, B., Krause, S., Elek, L. P., Sharma, S., & Tarazi, F. I. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.05.010 · Cited by 15
Saguin, E., Hulot, L. J., Roseau, J.-B., Metlaine, A., Paul, F., Nicolas, F., Sipahimalani, G., Léger, D., Gomez-Mérino, D., & Chennaoui, M. (2022) · Military Medicine · doi:10.1093/milmed/usac107 · Cited by 14
Mallet, C., Chick, C. F., Maatoug, R., Fossati, P., Brunet, A., & Millet, B. (2022) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10010 · Cited by 13
“11 However, to date, the effects of this protocol on sleep-related problems, particularly nightmares, has not been specifically evaluated.”
Groenink, L., Verdouw, P. M., Zhao, Y., ter Heegde, F., Wever, K. E., & Bijlsma, E. Y. (2023) · Psychopharmacology · doi:10.1007/s00213-022-06307-1 · Cited by 13
“The α 1 - adrenoceptor agonist prazosin has been shown to alleviate symptoms of PTSD (Raskind et al. 2003; Reist et al. 2021), but these potentially beneficial effects of prazosin are not unequivocal (Raskind et al 2018; Hendrickson et al 2021).”
BackgroundNorred, M. A., Zuschlag, Z. D., & Hamner, M. B. (2024) · Drugs · doi:10.1007/s40265-023-01983-5 · Cited by 17
“The benefit of prazosin has been mixed, with early data being promising and a recent randomized controlled trial (RCT) showing no difference between prazosin and placebo with improving PTSD symptoms, including sleep symptoms [28].”
Hendrickson, R. C., Millard, S. P., Pagulayan, K. F., Peskind, E. R., & Raskind, M. A. (2021) · Chronic Stress · doi:10.1177/2470547020979780 · Cited by 15
“Prazosin, an antagonist of the a1 adrenoceptor (AR), has been found effective in reducing the symptoms of Posttraumatic Stress Disorder (PTSD) in six randomized controlled trials (RCTs), although a seventh RCT of prazosin for PTSD was negative.(7) Prazosin’s use in PTSD was initially focused on recurrent distressing d…”
BackgroundResultSelf-citationPost traumatic stress and sleep disorders in long COVID: Patient management and treatment
Herring, T. E., Chopra, A., Friedly, J. L., Bender, J. A., Gentile, N. L., & Knowles, L. M. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123081 · Cited by 14
The Walking Wounded: Emerging Treatments for PTSD
Bestha, D. P., Soliman, L., Blankenship, K. M., & Rachal, J. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0941-8 · Cited by 13
Gao, X., Abdelkarim, H., Albee, L. J., Volkman, B. F., Gaponenko, V., & Majetschak, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204041 · Cited by 14
Augmenting Treatment for Posttraumatic Stress Disorder and Co-Occurring Conditions with Oxytocin
Flanagan, J. C., & Mitchell, J. (2019) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-019-00171-1 · Cited by 13
Verplaetse, T. L., Ralevski, E., Roberts, W., Gueorguieva, R. V., McKee, S. A., & Petrakis, I. L. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13969 · Cited by 12
“Prazosin has also demonstrated efficacy in decreasing nightmares and sleep disturbances in individuals with posttraumatic stress disorder (PTSD; Peskind et al., 2003; Raskind et al., 2000, 2002, 2003, 2007, 2013), although results are mixed (Raskind et al., 2018).”
A new meta-analysis of sleep findings in PTSD, toward integration and coherence
Mellman, T. A. (2019) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2019.101220 · Cited by 12
Self-citationTraumatic brain injury and sleep in military and veteran populations: A literature review
Landvater, J., Kim, S. Y., Caswell, K., Kwon, C., Odafe, E., Roe, G., Tripathi, A., Vukovics, C., Wang, J., Ryan, K., et al. (2024) · Neurorehabilitation · doi:10.3233/nre-230380 · Cited by 15
Proposing Bromo-Epi-Androsterone (BEA) for Post-Traumatic Stress Disorder (PTSD)
Dow, C. T., & Obaid, L. (2025) · Cells · doi:10.3390/cells14141120 · Cited by 11
“While propranolol and prazosin target PTSD’s adrenergic dysregulation, they are not established treatments for depression or epilepsy, though prazosin may reduce suicidal ideation in veterans with PTSD [95].”
Golier, J. A., Li, X., Bizien, M. D., Hurley, R. A., Bechard, B. W., Kimbrell, T. A., Flory, J. D., Baker, D. G., Yehuda, R., & Reda, D. J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.10223 · Cited by 12
Danan, E. R., Ullman, K. E., Klap, R. S., Yano, E. M., & Krebs, E. E. (2019) · Women s Health Issues · doi:10.1016/j.whi.2019.04.011 · Cited by 11
Reinhard, M. A., Seifert, J., Greiner, T., Toto, S., Bleich, S., & Grohmann, R. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01223-x · Cited by 12
Magnin, C., Poulet, E., Fanton, L., Vignaud, P., & Brunelin, J. (2023) · European Journal of Psychotraumatology · doi:10.1080/20008066.2023.2251250 · Cited by 10
“…there is a controversy about the efficacy of prazosin for global PTSD symptoms in patients with chronic PTSD (Reist et al., 2021), such as veterans (Raskind et al., 2018), its value in preventing the transition to full-blown PTSD in the early phase after trauma exposure, such as in patients with…”
BackgroundDelapaz, N. R., Hor, W. K., Gilbert, M., La, A. D., Liang, F., Fan, P., Qi, X., Guo, X., Ying, J., Sakolsky, D. J., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030178 · Cited by 14
“However, a large multisite randomized controlled trial of military veterans with chronic PTSD showed prazosin to be ineffective at reducing distressing dreams or improve sleep quality [7].”
BackgroundGuo, P., Yu, F., Feng, M., Zhao, X., Wang, S., Qian, M., Huang, J., & Chen, H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.803220 · Cited by 12
“It was also reported that prazosin was ineffective in alleviating sleep disturbance in PTSD veterans (10).”
BackgroundTheranostic pharmacology in PTSD: Neurobiology and timing
Koek, R. J., & Luong, T. N. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.12.001 · Cited by 10
Trauma-Associated Sleep Disorder
Barone, D. A. (2023) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2023.10.005 · Cited by 9
Shiner, B. R., Huybrechts, K. F., Gui, J., Rozema, L. R., Forehand, J. A., Watts, B. V., Jiang, T., Hoyt, J. E., Esteves, J., Schnurr, P. P., et al. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac104 · Cited by 11
Garriques, V. R., Dhruve, D. M., & Nadorff, M. R. (2023) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2023.10.011 · Cited by 9
Stanicic, F., Zah, V., Grbic, D., Vukicevic, D., & de Angelo, D. (2025) · PLoS ONE · doi:10.1371/journal.pone.0327778 · Cited by 11
“[60,62,69,79,80,84].”
InfluentialFellman, V., Heppell, P. J., & Rao, S. (2020) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2020.09.002 · Cited by 8
The Role of the Glutamate System in Posttraumatic Stress Disorder and Glutamate-Based Treatments
Popoli, M., Ieraci, A., & Musazzi, L. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_5 · Cited by 9
Erickson, B., Ehrie, J., Murray, S., Dougherty, R. J., Wainberg, M. L., Dixon, L. B., & Goldman, M. L. (2022) · Psychiatric Services · doi:10.1176/appi.ps.20220196 · Cited by 9
Autonomic regulation during sleep in PTSD
Woodward, S. H. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100483 · Cited by 9
Doxazosin for the treatment of nightmare disorder: A diary-based case study
Pallesen, S., Hamre, H. S., Lang, N., & Bjorvatn, B. (2020) · SAGE Open Medical Case Reports · doi:10.1177/2050313x20936079 · Cited by 13
Zhang, Y., Ren, R., Sanford, L. D., & Tang, X. (2020) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2020.101285 · Cited by 8
von Spreckelsen, P., Schouten, D., Waslam, N. G., Katuin, P., Heering, H. D., Planting, C., Antypa, N., Kivelä, L., Lancel, M., & Schweren, L. J. S. (2025) · Sleep Medicine: X · doi:10.1016/j.sleepx.2025.100145 · Cited by 7
“Prazosin was also examined in one safety study [85], which found 15 cases of suicidal ideation in the experimental group ( n = 152) and 23 cases of suicidal ideation in the control group ( n = 152).”
Fellman, V., Heppell, P. J., & Rao, S. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.06.015 · Cited by 8
Crump, C., Abuelazm, H., Ibrahim, K., Shah, S. R., & El‐Mallakh, R. S. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2367695 · Cited by 7
“However, any anxiogenic effect of the increased norepinephrine release is attenuated through blockade of postsynaptic alpha1 receptors in a manner similar to how prazosin reduces symptoms of post-traumatic stress disorder [29].”
Clonidine for post-traumatic stress disorder: a systematic review of the current evidence
Marchi, M., Grenzi, P., & Boks, M. P. (2024) · European Journal of Psychotraumatology · doi:10.1080/20008066.2024.2366049 · Cited by 9
“…drugs such as clonidine and guanfacine, which stimulate presynaptic alpha-2 adre-noceptors and thus inhibit adrenergic tone, may be bene fi cial for treating PTSD-related sleep disorders (Davis et al., 2008; Jagtiani et al., 2024; Khan et al., 1999; Raskind et al., 2018; Zhang et al., 2020).”
BackgroundResultGuo, P., Xu, Y., Lv, L., Feng, M., Fang, Y., Cheng, S., Xiao, X., Huang, J., Sheng, W., Wang, S., et al. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13763 · Cited by 7
“31 In this study, participants in the prazosin group had a faster efficacy, and anxiety and depression symptoms were improved after 3 days, with the potential mechanism of targeting insomnia and nightmares to alleviate depressive symptoms and anxiety.”
Pharmacological treatments for co-occurring PTSD and substance use disorders: A systematic review
Swannell, M., Bradlow, R. C. J., Pham, D., Gabriel, J., Manahan, Y., & Arunogiri, S. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209601 · Cited by 9
The Fall Risk with Alpha blockers Given InitiaL dose or Elderly status (FRAGILE) Study
McDonnell, C. C., Rogers, K. C., Regen, S. M., & Finks, S. W. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019880305 · Cited by 7
Clinical Use of Prazosin in a Patient With Acute Stress Disorder: A Case Report
Srivastava, A. A., & Opler, D. J. (2020) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000468 · Cited by 7
Baig, M. R., Beck, R. D., Wilson, J. L., Lemmer, J. A., Meraj, A., Meyer, E. C., Mintz, J., Peterson, A. L., & Roache, J. D. (2020) · Military Medical Research · doi:10.1186/s40779-020-00278-0 · Cited by 7
Posttraumatic Stress Disorder in the Primary Care Setting: Summary of Recommended Care
Spottswood, M., Fortney, J. C., Chen, J. A., Davydow, D. S., & Huang, H. Y. (2019) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000201 · Cited by 10
“Some evidence supports using prazosin for symptoms of hyperarousal and sleep difficulties,(37,48) although a recent study showed lack of efficacy in a heterogeneous population.(51)”
InfluentialAcute prazosin administration does not reduce stressor reactivity in healthy adults
Kaye, J. T., Fronk, G. E., Zgierska, A. E., Cruz, M. R., Rabago, D., & Curtin, J. J. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05297-x · Cited by 7
Traitements de la maladie des cauchemars
Perrier, A., Brion, A., Maruani, J., Romier, A., Sabbagh, O., Dufayet, G., Lejoyeux, M., & Geoffroy, P. A. (2021) · Médecine du Sommeil · doi:10.1016/j.msom.2021.05.003 · Cited by 9
Post-traumatic stress disorder
Ressler, K. J., Rothbaum, B. O., Schnurr, P. P., Binder, E., Moreland-Capuia, A. R., Nievergelt, C. M., Koenen, K. C., Seedat, S., Shalev, A. Y., Marmar, C. R., et al. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00701-1 · Cited by 8
“However, prazosin failed to demonstrate efficacy in a large randomized controlled trial in veterans 182 .”
Wu, J., Yu, L., Li, K., Zhang, D., Ye, L., Xu, X., Zhou, J., Li, Z., & Xu, H. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c01173 · Cited by 6
Fernandes, S. N., Zuckerman, E., Miranda, R., & Baroni, A. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.06.017 · Cited by 7
Post-traumatic Stress Disorder
Hudak, R., & Gannon, J. M. (2022) · Current clinical practice · doi:10.1007/978-3-030-98709-1_7 · Cited by 6
Haass‐Koffler, C. L. (2023) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15014 · Cited by 6
Case series: Continued remission of PTSD symptoms after discontinuation of prazosin
Richardson, C. S., Yuh, J. Y., Su, J., & Forsberg, M. M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1172754 · Cited by 6
“and other advocates believe strongly that clinicians should consider prazosin, although one of their clinical trials showed no improvement in nightmares or sleep quality (5).”
BackgroundA Meaningful Step Toward Understanding the Cause and Impact of Nightmares
Nadorff, M. R., Titus, C. E., & Pate, A. R. (2019) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.7608 · Cited by 6
Zhao, Y.-F., Huang, C., Zhang, Z., Liu, R.-B., Liu, J.-L., Li, X., Guo, G., & Zhang, C. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07157-9 · Cited by 5
“Our research involved a variety of pharmacotherapy types, alpha blockers [50–53, 55] , cannabis”
Baldini, V., Gnazzo, M., Varallo, G., Ronchi, D. D., Pizza, F., Plazzi, G., & Antelmi, E. (2026) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2026.102245 · Cited by 7
Obi, T., & Ressler, K. J. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02371-9 · Cited by 7
“Unfortunately, in the largest trial to date in US veterans, prazosin failed to separate from control [47], suggesting that there are individual differences and further pointing to the importance of identifying biomarkers that may differentiate which medication approaches are best for which patients.”
Insomnia medications: History, characteristics, and guidelines for optimal use in clinical practice
Krystal, A. D. (2023) · Journal of Sleep Research · doi:10.1111/jsr.14084 · Cited by 6
“…small randomised placebo-controlled reported significant therapeutic effects of prazosin versus placebo in this setting but, by far the largest study assessing this treat-ment, did not find a significant effect versus placebo on the Pittsburgh Sleep Quality Index (PSQI) (Raskind et al., 2018).”
BackgroundInfluentialElectrochemical Oxidation Decarboxylative Cyclization of α-Keto Acid with o-Aminobenzylamine
Wu, J., He, J. H., Wang, J., Li, L., Xu, C., Zhou, J., Li, Z., & Xu, H. (2024) · Chinese Journal of Organic Chemistry · doi:10.6023/cjoc202310015 · Cited by 5
Manhapra, A., Ralevski, E., & Petrakis, I. L. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.07.011 · Cited by 5
Havens, J., Hughes, J. H., McMaster, F., & Kingerlee, R. (2018) · Military Behavioral Health · doi:10.1080/21635781.2018.1526148 · Cited by 6
“However, a recent trial involving 312 military veterans with chronic PTSD failed to show any impact (Raskind et al., 2018), and U.S. Veterans Administration (VA) have ceased to recommend this as a treatment for PTSD nightmares (Department of Veterans Affairs & Department of Defence, 2017).”
BackgroundManukhina, E. B., Mallet, M. K., Цейликман, В. Э., Kondashevskaya, М. V., Буданова, О. П., Downey, H. F., & Mallet, R. T. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44081 · Cited by 4
“The α 1 -adrenergic antagonist prazosin and non-selective β -adrenergic antagonist propranolol have proven efficacious as off-label treatment for managing PTSD symptoms, including nightmares and arousal [147–149].”
Sleep disturbances in posttraumatic stress disorder: Current knowledge and clinical management
Saguin, E., & Rolling, J. (2026) · L Encéphale · doi:10.1016/j.encep.2026.02.004 · Cited by 5
Bernath, O., & Ward, R. (2023) · Somnologie - Schlafforschung und Schlafmedizin · doi:10.1007/s11818-023-00412-9 · Cited by 4
Miranda, O., Qi, X., Brannock, D., Whitworth, R., Kosten, T. R., Ryan, N. D., Haas, G. L., Kirisci, L., & Wang, L. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1526488 · Cited by 4
Sleep and PTSD: delving deeper to understand a complicated relationship
Swift, K. M. (2020) · SLEEP · doi:10.1093/sleep/zsaa074 · Cited by 15
Rubin, M. L., Copeland, L. A., Kroll‐Desrosiers, A., & Knittel, A. G. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4605 · Cited by 4
Sleep Disorders in Veterans: Prevalence, Consequences, and Treatment
Colvonen, P. J., Rivera, G. L., & Park, J. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-44447-1_16 · Cited by 4
Fletcher, K. E., Steinbach, S., Lewis, F., Hendricks, M., & Kwan, B. (2020) · Journal of Hospital Medicine · doi:10.12788/jhm.3409 · Cited by 5
Martin, A., Kosari, S., Peterson, G. M., Thomas, J., Morris, P., & Naunton, M. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13274 · Cited by 4
[A Review of the Posttraumatic Stress Disorder and Sleep Disturbances].
Zhang, Y., Ren, R., Yang, L., & Tang, X. (2021) · 四川大学学报:医学版 · doi:10.12182/20210160201 · Cited by 4
Sex and Age Differences in Glucocorticoid Signaling After an Aversive Experience in Mice
Li, Y., Zhang, B., Yang, Y., Su, P., Samsom, J., Wong, A. H. C., & Liu, F. (2024) · Cells · doi:10.3390/cells13242041 · Cited by 5
Park, N., Rouvere, J., Chase, E., Blanchard, B. E., Kaysen, D. L., Hendrickson, R. C., Fortney, J. C., & Cerimele, J. M. (2025) · Journal of Traumatic Stress · doi:10.1002/jts.23132 · Cited by 4
“Other than a weak recommendation for prazosin for nightmares, the VA guidelines do not clearly recommend interventions for insomnia or other sleep problems (Raskind et al., 2018; VA/DoD, 2023).”
Meakin, C., Fraser, G. A., Boisvert, D., & Miller, C. (2020) · Journal of Military Veteran and Family Health · doi:10.3138/jmvfh-2019-0028 · Cited by 4
Predictors of PTSD Treatment Retention and Response: A Systematic Review
Maglione, M., Chen, C., Franco, M., Gizaw, M., Shahidinia, N., Baxi, S. M., & Hempel, S. (2022) · RAND Corporation eBooks · doi:10.7249/rr4191 · Cited by 5
Sleep Medicine and the Evolution of Contemporary Sleep Pharmacotherapy
Larrivee, D. C. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.91536 · Cited by 5
Prazosin dosed 3 times a day to treat flashbacks related to PTSD: A case report
Richardson, C. S., Swartz, A., & Forsberg, M. M. (2022) · Mental Health Clinician · doi:10.9740/mhc.2022.08.267 · Cited by 5
“2 mg.(5,6,7) The patient’s flashbacks were reduced with prazosin 1 mg in the morning; however, she felt the effects were wearing off in the afternoon.”
BackgroundPrajjwal, P., Inban, P., Natarajan, B., Mitra, S., Tango, T., Ahmed, A., Bansode, S., & Almushawah, A. A. (2022) · Cureus · doi:10.7759/cureus.31943 · Cited by 5
“While a more recent big Veterans Affairs Cooperative Study with negative outcomes had inconsistent findings about the efficacy of the drug [27], prior guidelines that were based on smaller favorable trials advocated the use of prazosin.”
ResultPost-traumatic Stress Disorder and Other Trauma-Related Disorders
Aron, C. M., & LeFay, S. M. (2022) · Springer eBooks · doi:10.1007/978-3-031-08364-8_8 · Cited by 4
Social support for veterans taking part in military service outside their country’s borders
Mendrek, P., Osiak, B., & Goniewicz, K. (2019) · Health Psychology Report · doi:10.5114/hpr.2019.87289 · Cited by 4
Prazosin Outcomes in Older Veterans With Posttraumatic Stress Disorder.
Khaw, C., & Argo, T. R. (2020) · PubMed · Cited by 5
Metadata
- Authors
- Raskind, M. A., Peskind, E. R., Chow, B., Harris, C., Davis-Karim, A., Holmes, H. A., Hart, K. L., McFall, M., Mellman, T. A., Reist, C., Romesser, J., Rosenheck, R., Shih, M.-C., Stein, M. B., Swift, R., Gleason, T., Lu, Y., & Huang, G. D.
- Affiliations
- University of Washington (US)
- From the Veterans Affairs (VA) Northwest Network Mental Illness Research, Education, and Clinical Center (M.A.R., E.R.P., H.A.H., K.L.H., M.M.) and the Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine (M.A.R., E.R.P., M.M.), Seattle; VA Cooperative Studies Program Coordinating Center, Palo Alto (B.C., M.-C.S., Y.L.), VA Long Beach Healthcare System, Department of Human Behavior, University of California, Irvine (C.R.), the Department of Health Research...
- Howard University (US)
- United States Department of Veterans Affairs (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02-08
- Volume
- 378
- Issue
- 6
- Pages
- 507-517
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2789959403
- Cited by
- 342
- References
- 31
- Citations by year
- 2026: 34 · 2025: 31 · 2024: 44 · 2023: 25 · 2022: 49 · 2021: 39 · 2020: 51 · 2019: 40 · 2018: 28
- FWCI
- 46.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- VA Cooperative Studies Program.
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
- Keywords
- prazosin, post-traumatic stress disorder, military veterans, nightmares, chronic PTSD, alpha-blockers, sleep quality, blood pressure, adverse effects, PTSD pharmacotherapy, sleep disorders, sleep quality index, Clinician-Administered PTSD Scale, Clinical Global Impression of Change, dose escalation
- MeSH terms
- Adult, Combined Modality Therapy, Dose-Response Relationship, Drug, Double-Blind Method, Dreams, Female, Hospitals, Veterans, Humans, Male, Middle Aged, Prazosin, Psychiatric Status Rating Scales, Psychotherapy, Sleep, Sleep Wake Disorders, Stress Disorders, Post-Traumatic, United States, Veterans, Treatment Failure, Adrenergic alpha-1 Receptor Antagonists, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.